Search Medical Condition
Please enter condition
Please choose location from dropdown

Montfleury, Tunisia Clinical Trials

A listing of Montfleury, Tunisia clinical trials actively recruiting patients volunteers.

RESULTS

Found (27) clinical trials

A Rollover Study to Provide Continued Treatment With Eltrombopag

This study will provide continued access to treatment with eltrombopag for subjects who are currently participating in a GlaxoSmithKline (GSK) sponsored investigational study of eltrombopag (parent study) and to collect long term safety data.

Phase

0.0 miles

Learn More »

Study to Evaluate Treatment Compliance Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

This is a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance and change in serum ferritin of a deferasirox granule formulation and a deferasirox DT formulation in children and adolescents aged 2 and < 18 years at enrollment with any transfusion-dependent anemia requiring chelation therapy due ...

Phase

1.42 miles

Learn More »

Comparison of Thromboembolic Events Between Enoxa and Lovenox in Patients Undergoing Digestive Cancer

Comparative study with two arms versus ENOXA® LOVENOX®, randomized, prospective, single-center, with rater-blinded whose main objective is to compare the incidence of thromboembolic events (symptomatic and asymptomatic) between the two arms of the study, in patients undergoing digestive cancer and receiving thromboprophylaxis based SODIUM enoxaparin.

Phase

1.42 miles

Learn More »

EDS in Ataxia Telangiectasia Patients

All patients who complete the assessments as designed over the initial 6 months of the trial will be eligible to continue in an additional 6-month, double-blind, placebo-controlled extension designed to collect information on the long-term safety and efficacy of the trial treatments. Upon completion of all screening assessments for eligibility ...

Phase

1.42 miles

Learn More »

Global Non-interventional Heart Failure Disease Registry

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for ...

Phase N/A

1.42 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

1.42 miles

Learn More »

Efficacy and Safety Study of I10E in Treatment of Patients With CIDP

Primary objective: To assess the efficacy of I10E in improving the disability of patients with CIDP. Secondary objective: To assess the safety of I10E in patients with CIDP.

Phase

1.42 miles

Learn More »

Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302

Primary objective: To assess the efficacy of I10E administered at a reduced maintenance dose in sustaining CIDP response after an initial 6-month treatment in PRISM study. (I10E-1302). Secondary objective: To assess the safety of I10E in this patient population.

Phase

1.42 miles

Learn More »

Efficacy Safety Pharmacodynamic and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

The total duration per patient is at least 3 years and up to 5 years and 3 months. This includes up to approximately two month of screening, 52 weeks of primary analysis period, up to 4 years and 3 months of extension treatment period, an end-of- study visit within 2 ...

Phase

1.42 miles

Learn More »

Efficacy and Safety of Ferriprox in Patients With Sickle Cell Disease or Other Anemias

Deferiprone (brand name Ferriprox) is an iron chelator that is approved in the United States and over 60 other countries for the treatment of iron overload in patients with thalassemia, when other treatments are inadequate. This study has been designed to evaluate the efficacy, safety, and tolerability of deferiprone vs. ...

Phase

1.42 miles

Learn More »